DE602005019038D1 - O-verknüpfte glykoformen von faktor vii und verfahren zu deren herstellung - Google Patents
O-verknüpfte glykoformen von faktor vii und verfahren zu deren herstellungInfo
- Publication number
- DE602005019038D1 DE602005019038D1 DE602005019038T DE602005019038T DE602005019038D1 DE 602005019038 D1 DE602005019038 D1 DE 602005019038D1 DE 602005019038 T DE602005019038 T DE 602005019038T DE 602005019038 T DE602005019038 T DE 602005019038T DE 602005019038 D1 DE602005019038 D1 DE 602005019038D1
- Authority
- DE
- Germany
- Prior art keywords
- factor vii
- production
- glyco forms
- linked glyco
- linked
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200400712 | 2004-05-04 | ||
DKPA200400882 | 2004-06-04 | ||
PCT/EP2005/052024 WO2005111225A1 (en) | 2004-05-04 | 2005-05-03 | O-linked glycoforms of polypeptides and method to manufacture them |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602005019038D1 true DE602005019038D1 (de) | 2010-03-11 |
Family
ID=34968774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602005019038T Active DE602005019038D1 (de) | 2004-05-04 | 2005-05-03 | O-verknüpfte glykoformen von faktor vii und verfahren zu deren herstellung |
Country Status (15)
Country | Link |
---|---|
US (3) | US20080305518A1 (de) |
EP (1) | EP1745141B2 (de) |
JP (2) | JP5826446B2 (de) |
KR (1) | KR20070008645A (de) |
AT (1) | ATE455861T1 (de) |
AU (1) | AU2005243427B2 (de) |
BR (1) | BRPI0510295A (de) |
CA (1) | CA2565414A1 (de) |
DE (1) | DE602005019038D1 (de) |
ES (1) | ES2339953T5 (de) |
IL (1) | IL178541A0 (de) |
MX (1) | MXPA06012676A (de) |
NO (1) | NO20065512L (de) |
RU (1) | RU2006138181A (de) |
WO (1) | WO2005111225A1 (de) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7157277B2 (en) * | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US8008252B2 (en) | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
AU2004236174B2 (en) | 2001-10-10 | 2011-06-02 | Novo Nordisk A/S | Glycopegylation methods and proteins/peptides produced by the methods |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
CA2519092C (en) | 2003-03-14 | 2014-08-05 | Neose Technologies, Inc. | Branched water-soluble polymers and their conjugates |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
ES2380093T3 (es) | 2003-05-09 | 2012-05-08 | Biogenerix Ag | Composiciones y métodos para la preparación de mutantes de glucosilación de la hormona del crecimiento humana |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
CN101072789B (zh) | 2004-01-08 | 2013-05-15 | 生物种属学股份公司 | 肽的o-连接的糖基化 |
KR20070008645A (ko) * | 2004-05-04 | 2007-01-17 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 폴리펩티드의 o-연결된 단백당형 및 그들의 제조 방법 |
WO2006010143A2 (en) | 2004-07-13 | 2006-01-26 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1] |
EP1799249A2 (de) | 2004-09-10 | 2007-06-27 | Neose Technologies, Inc. | Glycopegyliertes interferon alpha |
EP1814573B1 (de) | 2004-10-29 | 2016-03-09 | ratiopharm GmbH | Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf) |
NZ556436A (en) | 2005-01-10 | 2010-11-26 | Biogenerix Ag | Glycopegylated granulocyte colony stimulating factor |
US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
JP5216580B2 (ja) | 2005-05-25 | 2013-06-19 | ノヴォ ノルディスク アー/エス | グリコペグ化第ix因子 |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
ES2515915T3 (es) * | 2005-09-01 | 2014-10-30 | Novo Nordisk Health Care Ag | Purificación de los polipéptidos del Factor VII mediante cromatografía de interacción hidrofóbica |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
EP1816201A1 (de) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät |
CA2649199C (en) * | 2006-04-11 | 2015-01-20 | Csl Behring Gmbh | Method of increasing the in vivo recovery of therapeutic polypeptides |
JP2009544327A (ja) | 2006-07-21 | 2009-12-17 | ノヴォ ノルディスク アー/エス | O−結合型グリコシル化配列によるペプチドのグリコシル化 |
US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
CA2910619A1 (en) | 2006-09-13 | 2008-03-20 | Abbvie Inc. | Cell culture improvements |
JP2010505874A (ja) | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー/エス | ポリペプチドコンジュゲートの精製方法 |
EP2097096B1 (de) | 2006-12-22 | 2017-05-31 | CSL Behring GmbH | Veränderte koagulationsfaktoren mit verlängerter in vivo halbwertzeit |
KR20150064246A (ko) | 2007-04-03 | 2015-06-10 | 바이오제너릭스 게엠베하 | 글리코페길화 g―csf를 이용하는 치료 방법 |
JP5876649B2 (ja) | 2007-06-12 | 2016-03-02 | ラツィオファルム ゲーエムベーハーratiopharm GmbH | ヌクレオチド糖の改良製造法 |
US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
CN104004739A (zh) * | 2007-10-15 | 2014-08-27 | 北卡罗来纳-查佩尔山大学 | 半衰期延长的人因子ix变体 |
CN103497246B (zh) | 2008-02-27 | 2016-08-10 | 诺沃—诺迪斯克有限公司 | 缀合的因子viii分子 |
TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子vii多肽和其用途 |
US8876688B2 (en) | 2008-04-24 | 2014-11-04 | The Invention Science Fund I, Llc | Combination treatment modification methods and systems |
US9239906B2 (en) | 2008-04-24 | 2016-01-19 | The Invention Science Fund I, Llc | Combination treatment selection methods and systems |
US9064036B2 (en) | 2008-04-24 | 2015-06-23 | The Invention Science Fund I, Llc | Methods and systems for monitoring bioactive agent use |
US8615407B2 (en) | 2008-04-24 | 2013-12-24 | The Invention Science Fund I, Llc | Methods and systems for detecting a bioactive agent effect |
US20100130811A1 (en) * | 2008-04-24 | 2010-05-27 | Searete Llc | Computational system and method for memory modification |
US8682687B2 (en) * | 2008-04-24 | 2014-03-25 | The Invention Science Fund I, Llc | Methods and systems for presenting a combination treatment |
US20100069724A1 (en) * | 2008-04-24 | 2010-03-18 | Searete Llc | Computational system and method for memory modification |
US9649469B2 (en) | 2008-04-24 | 2017-05-16 | The Invention Science Fund I Llc | Methods and systems for presenting a combination treatment |
US9282927B2 (en) | 2008-04-24 | 2016-03-15 | Invention Science Fund I, Llc | Methods and systems for modifying bioactive agent use |
US8606592B2 (en) | 2008-04-24 | 2013-12-10 | The Invention Science Fund I, Llc | Methods and systems for monitoring bioactive agent use |
US8930208B2 (en) | 2008-04-24 | 2015-01-06 | The Invention Science Fund I, Llc | Methods and systems for detecting a bioactive agent effect |
US9026369B2 (en) | 2008-04-24 | 2015-05-05 | The Invention Science Fund I, Llc | Methods and systems for presenting a combination treatment |
US9662391B2 (en) | 2008-04-24 | 2017-05-30 | The Invention Science Fund I Llc | Side effect ameliorating combination therapeutic products and systems |
US9449150B2 (en) | 2008-04-24 | 2016-09-20 | The Invention Science Fund I, Llc | Combination treatment selection methods and systems |
US9560967B2 (en) | 2008-04-24 | 2017-02-07 | The Invention Science Fund I Llc | Systems and apparatus for measuring a bioactive agent effect |
TW201024318A (en) | 2008-10-20 | 2010-07-01 | Abbott Lab | Isolation and purification of antibodies using protein A affinity chromatography |
CA2738499A1 (en) | 2008-10-20 | 2010-04-29 | Abbott Laboratories | Viral inactivation during purification of antibodies |
EP2702077A2 (de) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen |
UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
AU2013309506A1 (en) | 2012-09-02 | 2015-03-12 | Abbvie Inc. | Methods to control protein heterogeneity |
US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
SG10201809779RA (en) | 2013-03-11 | 2018-12-28 | Genzyme Corp | Site-specific antibody-drug conjugation through glycoengineering |
CA2905010A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
US9175279B1 (en) | 2013-03-15 | 2015-11-03 | Csl Limited | Method of purifying factor VII and/or factor VIIa |
SG11201601823TA (en) | 2013-09-13 | 2016-04-28 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
EP3052640A2 (de) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Verwendung von metallionen zur modulation von proteinglykosylierungsprofilen rekombinanter proteine |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
ES2940903T3 (es) | 2014-03-19 | 2023-05-12 | Genzyme Corp | Glucomanipulación específica del sitio de restos orientadores |
MX2017004664A (es) | 2014-10-09 | 2017-06-30 | Genzyme Corp | Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria. |
US10494405B2 (en) | 2015-05-15 | 2019-12-03 | The Regents Of The University Of Michigan | Methods and compositions for the treatment of arthritis |
EP3833381B1 (de) | 2019-08-15 | 2022-08-03 | Catalyst Biosciences, Inc. | Modifizierte faktor-vii-polypeptide zur subkutanen verabreichung |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1479268A (en) * | 1973-07-05 | 1977-07-13 | Beecham Group Ltd | Pharmaceutical compositions |
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
CH596313A5 (de) * | 1975-05-30 | 1978-03-15 | Battelle Memorial Institute | |
US4385260A (en) * | 1975-09-09 | 1983-05-24 | Beckman Instruments, Inc. | Bargraph display |
US4414147A (en) * | 1981-04-17 | 1983-11-08 | Massachusetts Institute Of Technology | Methods of decreasing the hydrophobicity of fibroblast and other interferons |
JPS57206622A (en) * | 1981-06-10 | 1982-12-18 | Ajinomoto Co Inc | Blood substitute |
US4496689A (en) * | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
WO1987000056A1 (en) | 1985-06-26 | 1987-01-15 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
JPS6238172A (ja) * | 1985-08-12 | 1987-02-19 | 株式会社 高研 | 抗血栓性医用材料の製造方法 |
US4925796A (en) * | 1986-03-07 | 1990-05-15 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US6166183A (en) * | 1992-11-30 | 2000-12-26 | Kirin-Amgen, Inc. | Chemically-modified G-CSF |
ES2130120T3 (es) | 1988-12-23 | 1999-07-01 | Genentech Inc | Procedimiento para la preparacion de la adnasa humana. |
US5527527A (en) * | 1989-09-07 | 1996-06-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
US5182107A (en) * | 1989-09-07 | 1993-01-26 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
US5977307A (en) * | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
US5672683A (en) | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
US5154924A (en) * | 1989-09-07 | 1992-10-13 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
DE4009630C2 (de) * | 1990-03-26 | 1995-09-28 | Reinhard Prof Dr Dr Brossmer | CMP-aktivierte fluoreszierende Sialinsäuren sowie Verfahren zu ihrer Herstellung |
US5212075A (en) | 1991-04-15 | 1993-05-18 | The Regents Of The University Of California | Compositions and methods for introducing effectors to pathogens and cells |
US5352670A (en) * | 1991-06-10 | 1994-10-04 | Alberta Research Council | Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides |
US6037452A (en) * | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
US5614184A (en) * | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
AU5098193A (en) | 1992-09-01 | 1994-03-29 | Berlex Laboratories, Inc. | Glycolation of glycosylated macromolecules |
WO1994015625A1 (en) | 1993-01-15 | 1994-07-21 | Enzon, Inc. | Factor viii - polymeric conjugates |
US5374541A (en) * | 1993-05-04 | 1994-12-20 | The Scripps Research Institute | Combined use of β-galactosidase and sialyltransferase coupled with in situ regeneration of CMP-sialic acid for one pot synthesis of oligosaccharides |
US5621039A (en) * | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
SE9304316D0 (sv) * | 1993-12-24 | 1993-12-24 | Kurt Nilsson | Aminosyra-konjugat |
US5432059A (en) * | 1994-04-01 | 1995-07-11 | Specialty Laboratories, Inc. | Assay for glycosylation deficiency disorders |
DE69518246T2 (de) * | 1994-09-06 | 2000-12-21 | Ab Lund Bioflexin | Aminosäuren konjugaten |
US5545553A (en) * | 1994-09-26 | 1996-08-13 | The Rockefeller University | Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them |
US5834251A (en) * | 1994-12-30 | 1998-11-10 | Alko Group Ltd. | Methods of modifying carbohydrate moieties |
US5922577A (en) * | 1995-04-11 | 1999-07-13 | Cytel Corporation | Enzymatic synthesis of glycosidic linkages |
US6030815A (en) * | 1995-04-11 | 2000-02-29 | Neose Technologies, Inc. | Enzymatic synthesis of oligosaccharides |
US5728554A (en) * | 1995-04-11 | 1998-03-17 | Cytel Corporation | Enzymatic synthesis of glycosidic linkages |
US5876980A (en) * | 1995-04-11 | 1999-03-02 | Cytel Corporation | Enzymatic synthesis of oligosaccharides |
US6015555A (en) * | 1995-05-19 | 2000-01-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
WO1996040731A1 (en) | 1995-06-07 | 1996-12-19 | Mount Sinai School Of Medicine Of The City University Of New York | Pegylated modified proteins |
DE19531637A1 (de) * | 1995-08-28 | 1997-03-06 | Immuno Ag | Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung |
US5716812A (en) * | 1995-12-12 | 1998-02-10 | The University Of British Columbia | Methods and compositions for synthesis of oligosaccharides, and the products formed thereby |
TWI240627B (en) | 1996-04-26 | 2005-10-01 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
US6399336B1 (en) | 1997-01-16 | 2002-06-04 | Neose Technologies, Inc. | Practical in vitro sialylation of recombinant glycoproteins |
US6183738B1 (en) * | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
AT407255B (de) * | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
WO1998058964A1 (en) | 1997-06-24 | 1998-12-30 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
WO1999000150A2 (en) | 1997-06-27 | 1999-01-07 | Regents Of The University Of California | Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor |
ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
AT408613B (de) | 1998-06-17 | 2002-01-25 | Immuno Ag | Pharmazeutisches faktor vii-präparat |
DE19852729A1 (de) * | 1998-11-16 | 2000-05-18 | Werner Reutter | Rekombinante Glycoproteine, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und ihre Verwendung |
KR100767473B1 (ko) | 1999-05-31 | 2007-10-17 | 미쯔비시 가가꾸 가부시끼가이샤 | 간실질세포 증식인자 동결건조 제제 |
JP2001029095A (ja) * | 1999-07-26 | 2001-02-06 | Mitsui Chemicals Inc | N−アセチルラクトサミン繰り返し構造の含有割合を減少させる方法 |
WO2001049830A2 (en) | 1999-12-30 | 2001-07-12 | Maxygen Aps | Improved lysosomal enzymes and lysosomal enzyme activators |
AU2001232337A1 (en) | 2000-02-18 | 2001-08-27 | Kanagawa Academy Of Science And Technology | Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance |
ES2449224T3 (es) | 2000-05-03 | 2014-03-18 | Novo Nordisk Health Care Ag | Administración subcutánea del Factor de coagulación VII |
MXPA02011016A (es) * | 2000-05-12 | 2004-03-16 | Neose Technologies Inc | Glicopeptidos recombinantes de glucolisacion in vitro. |
ATE309385T1 (de) * | 2000-06-28 | 2005-11-15 | Glycofi Inc | Verfahren für die herstellung modifizierter glykoproteine |
AU2001267337A1 (en) | 2000-06-30 | 2002-01-14 | Maxygen Aps | Peptide extended glycosylated polypeptides |
WO2002013873A2 (en) | 2000-08-17 | 2002-02-21 | Synapse Technologies, Inc. | P97-active agent conjugates and their methods of use |
WO2002013843A2 (en) | 2000-08-17 | 2002-02-21 | University Of British Columbia | Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours |
EP1930024A3 (de) | 2000-09-01 | 2008-08-06 | Chugai Seiyaku Kabushiki Kaisha | G-CSF Lösungsformulierung mit Langzeitstabilität |
IL154879A0 (en) | 2000-10-02 | 2003-10-31 | Novo Nordisk As | Factor vii glycoforms |
DE60232434D1 (de) | 2001-02-27 | 2009-07-09 | Maxygen Aps | Neue interferon-beta-ähnliche moleküle |
EP1270551A1 (de) | 2001-06-26 | 2003-01-02 | Aventis Pharma Deutschland GmbH | Harnstoffverbindungen mit antiproteolytischer Wirkung |
US7265085B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycoconjugation methods and proteins/peptides produced by the methods |
ES2556338T3 (es) * | 2001-10-10 | 2016-01-15 | Novo Nordisk A/S | Remodelación y glicoconjugación de péptidos |
DE60228492D1 (de) | 2001-11-28 | 2008-10-02 | Neose Technologies Inc | Remodellierung von glycoproteinen unter verwendung von endoglycanasen |
JP2005530683A (ja) | 2001-12-21 | 2005-10-13 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 第vii因子ポリペプチドの液体組成物 |
WO2003055511A1 (en) | 2001-12-21 | 2003-07-10 | Novo Nordisk A/S | Liquid composition of modified factor vii polypeptides |
PT1517698E (pt) † | 2002-06-21 | 2014-11-19 | Novo Nordisk Healthcare Ag | Composições sólidas estabilizadas de polipéptidos do fator viia |
PL211175B1 (pl) | 2002-06-21 | 2012-04-30 | Novo Nordisk Healthcare Ag | Koniugat polipeptydu czynnika VII, sposób wytwarzania takiego koniugatu, zawierający taki koniugat preparat farmaceutyczny oraz zastosowanie takiego koniugatu |
EP1605968A2 (de) | 2003-03-18 | 2005-12-21 | Novo Nordisk Health Care AG | Flüssige, wässrige, pharmazeutische zusammensetzungen von faktor-vii-polypeptiden |
EP1646398A2 (de) | 2003-06-13 | 2006-04-19 | Novo Nordisk Health Care AG | Zusammensetzungen enthaltend faktor viia und faktor-vii-polypeptiden |
JP2007501812A (ja) | 2003-08-08 | 2007-02-01 | ノボ ノルディスク アクティーゼルスカブ | ペプチドのための結合剤として新しい構造上十分に定義された枝分れしたポリマーの合成および適用 |
CN101072789B (zh) * | 2004-01-08 | 2013-05-15 | 生物种属学股份公司 | 肽的o-连接的糖基化 |
KR20070008645A (ko) | 2004-05-04 | 2007-01-17 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 폴리펩티드의 o-연결된 단백당형 및 그들의 제조 방법 |
ES2515915T3 (es) | 2005-09-01 | 2014-10-30 | Novo Nordisk Health Care Ag | Purificación de los polipéptidos del Factor VII mediante cromatografía de interacción hidrofóbica |
-
2005
- 2005-05-03 KR KR1020067021693A patent/KR20070008645A/ko not_active Application Discontinuation
- 2005-05-03 US US11/579,401 patent/US20080305518A1/en not_active Abandoned
- 2005-05-03 ES ES05766825T patent/ES2339953T5/es active Active
- 2005-05-03 WO PCT/EP2005/052024 patent/WO2005111225A1/en active Application Filing
- 2005-05-03 BR BRPI0510295-2A patent/BRPI0510295A/pt not_active IP Right Cessation
- 2005-05-03 AT AT05766825T patent/ATE455861T1/de not_active IP Right Cessation
- 2005-05-03 AU AU2005243427A patent/AU2005243427B2/en not_active Expired - Fee Related
- 2005-05-03 RU RU2006138181/13A patent/RU2006138181A/ru not_active Application Discontinuation
- 2005-05-03 MX MXPA06012676A patent/MXPA06012676A/es unknown
- 2005-05-03 DE DE602005019038T patent/DE602005019038D1/de active Active
- 2005-05-03 CA CA002565414A patent/CA2565414A1/en not_active Abandoned
- 2005-05-03 JP JP2007512192A patent/JP5826446B2/ja not_active Expired - Fee Related
- 2005-05-03 EP EP05766825.3A patent/EP1745141B2/de not_active Not-in-force
-
2006
- 2006-10-15 IL IL178541A patent/IL178541A0/en unknown
- 2006-11-29 NO NO20065512A patent/NO20065512L/no not_active Application Discontinuation
-
2010
- 2010-09-17 US US12/884,927 patent/US9023992B2/en active Active
-
2013
- 2013-12-02 JP JP2013249652A patent/JP2014088391A/ja not_active Withdrawn
-
2017
- 2017-10-09 US US15/727,912 patent/US10844110B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10844110B2 (en) | 2020-11-24 |
JP2007536345A (ja) | 2007-12-13 |
EP1745141B2 (de) | 2019-09-25 |
KR20070008645A (ko) | 2007-01-17 |
AU2005243427A1 (en) | 2005-11-24 |
ES2339953T3 (es) | 2010-05-27 |
WO2005111225A1 (en) | 2005-11-24 |
EP1745141A1 (de) | 2007-01-24 |
AU2005243427B2 (en) | 2010-07-22 |
BRPI0510295A (pt) | 2007-11-06 |
US20080305518A1 (en) | 2008-12-11 |
US9023992B2 (en) | 2015-05-05 |
ES2339953T5 (es) | 2020-05-06 |
RU2006138181A (ru) | 2008-06-10 |
CA2565414A1 (en) | 2005-11-24 |
NO20065512L (no) | 2006-11-29 |
US20180057566A1 (en) | 2018-03-01 |
IL178541A0 (en) | 2007-02-11 |
US20110064719A1 (en) | 2011-03-17 |
ATE455861T1 (de) | 2010-02-15 |
JP5826446B2 (ja) | 2015-12-02 |
JP2014088391A (ja) | 2014-05-15 |
EP1745141B1 (de) | 2010-01-20 |
MXPA06012676A (es) | 2007-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602005019038D1 (de) | O-verknüpfte glykoformen von faktor vii und verfahren zu deren herstellung | |
ATE482966T1 (de) | Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide | |
ATE486841T1 (de) | Verfahren zur herstellung von pregabalin und salzen daraus | |
DE60218237D1 (de) | Kraftstofftank und Verfahren zu seiner Herstellung | |
ATE544754T1 (de) | Verfahren zur herstellung von ivabradinhydrochlorid | |
ATE403668T1 (de) | Verfahren zur herstellung von 3-oxo-pregn-4-en-21,17-carbolactonen durch die metallfreie oxidation von 17-(3-hydroxypropyl)-3,17- dihydroxyandrostanen | |
ATE489365T1 (de) | Verfahren und zwischenprodukte zur herstellung von (1r,2s,5s)-6,6-dimethyl-3-azabicycloä3,1,0 ühexan-2-carboxylaten oder salzen davon | |
DE602005019831D1 (de) | Verfahren zur Herstellung von keramischen Giessereikernen für Turbinenschaufeln | |
DE602006019924D1 (de) | Metalpartikel, Prozess zu deren Herstellung und Verfahren zur Herstellung von Automobilteilen daraus | |
ATE444950T1 (de) | Verfahren zur herstellung von 1-amino-3,5- dimethyladamantan-hydrochlorid | |
DE602004009642D1 (de) | Verfahren zur Herstellung eines Gegenstandes durch Diffusionsschweissen und superplastisches Verformen | |
DE502005007762D1 (de) | Verfahren zur herstellung von zahnrädern | |
ATE356136T1 (de) | Verfahren zur herstellung von 1,2- diaminocyclohexan-platin(ii)-komplexen | |
ATE458743T1 (de) | Zwischenprodukt und verfahren zur herstellung von an beta-anomeren angereicherten 2'-desoxy,2',2'- difluor-d-ribufuranosylnukleosiden | |
ATE488509T1 (de) | Verfahren zur herstellung von substituierten tetrazolen aus aminotetrazolen | |
DE102004035617B8 (de) | Verfahren zur Herstellung von Substraten für Fotomaskenrohlinge | |
DE502004006327D1 (de) | Verfahren zur herstellung von gasturbinenrotoren mit integraler beschaufelung durch kondensatorentladungsschweissen | |
ATE489352T1 (de) | Verfahren zur herstellung von brenztraubensäure | |
ATE517863T1 (de) | Verfahren zur herstellung von harnstoff | |
ATE417839T1 (de) | Verfahren zur herstellung von amorolfin | |
ATE478045T1 (de) | Derivate von 4,5-diarylpyrrol, verfahren zu deren herstellung und deren verwendung in therapeutika | |
DE60300144D1 (de) | Verfahren zur Herstellung von Al-Sinterlegierung | |
ATE501104T1 (de) | Verfahren zur herstellung von 1,2,2,2-tetrafluor- ethyl-difluor-methylether | |
ATE337796T1 (de) | Verfahren zur herstellung von hyperpolarisiertem 129xe | |
DE602006000087D1 (de) | Verfahren zur Herstellung von Mustern |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent |